Brokerages Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $5.08

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have been given a consensus recommendation of “Hold” by the four analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.08.

Several research analysts have weighed in on MCRB shares. StockNews.com lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, August 14th. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Friday, September 13th.

Seres Therapeutics Stock Down 0.7 %

Shares of Seres Therapeutics stock opened at $0.70 on Thursday. The business has a fifty day simple moving average of $0.89 and a 200 day simple moving average of $0.91. The stock has a market cap of $119.97 million, a PE ratio of -0.60 and a beta of 2.03. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $2.05.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same period in the prior year, the firm earned $0.36 earnings per share. Analysts expect that Seres Therapeutics will post -0.95 EPS for the current fiscal year.

Insider Activity at Seres Therapeutics

In other Seres Therapeutics news, insider Teresa L. Young sold 24,480 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.08, for a total value of $26,438.40. Following the completion of the transaction, the insider now directly owns 78,178 shares in the company, valued at $84,432.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 28,844 shares of company stock valued at $30,104. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Seres Therapeutics during the 1st quarter worth about $39,000. Providence Wealth Advisors LLC boosted its holdings in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 25,250 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Seres Therapeutics in the second quarter valued at approximately $64,000. Virtu Financial LLC bought a new position in shares of Seres Therapeutics during the first quarter worth approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics during the 2nd quarter worth approximately $92,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.